

# Effect of the Step-Jump Approach in Infected Pancreatic Necrosis: A Propensity Score-Matched Study

Rui Bai<sup>1,2</sup>, Yuhang Sui<sup>1,2</sup>, Tianqi Lu<sup>1,2</sup>, Hua Chen<sup>1,2</sup>, Gang Wang<sup>1,2</sup>, Rui Kong<sup>1,2</sup>, Hongtao Tan<sup>1,2</sup>, Yongwei Wang<sup>1,2</sup>, Guanqun Li<sup>1,2</sup>, Bei Sun<sup>1,2</sup>

<sup>1</sup>Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China; <sup>2</sup>Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China

Correspondence: Guanqun Li; Bei Sun, Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, No. 23 Youzheng Street, Nangang District, Harbin, 150001, People's Republic of China, Email [liguanqun@hrbmu.edu.cn](mailto:liguanqun@hrbmu.edu.cn); [sunbei70@hrbmu.edu.cn](mailto:sunbei70@hrbmu.edu.cn)



**Purpose:** The effects of the step-jump approach on the survival and prognosis of infected pancreatic necrosis (IPN) patients have not yet been determined.

**Patients and Methods:** Between November 2018 and June 2023, 188 patients were included in this study. There were 144 patients in the step-up group (the SU group) and 44 in the step-jump group (the SJ group). In the SU group, patients successfully treated with percutaneous catheter drainage (PCD) alone were classified into the SU-1 group (n=101), while those requiring additional surgery after PCD were categorized into the SU-2 group (n=43). In the SJ group, patients who underwent minimally invasive necrosectomy (MIN) without PCD were assigned to the SJ-1 group (n=34), whereas those who initially underwent PCD followed by immediate open surgery were placed in the SJ-2 group (n=10). Propensity score matching (PSM) was used to mitigate bias.

**Results:** After PSM, a total of 34 pairs were successfully matched. A comparison of the SU group with the SJ-1 group (upfront MIN without PCD) revealed similar mortality rates ( $P=0.239$ ); however, the incidences of multiple drug-resistant organisms (MDROs) ( $P=0.029$ ) and surgical complications ( $P<0.001$ ) were significantly lower in the SJ-1 group. After comparing the SU-2 and SJ-2 groups (patients who underwent direct open necrosectomy without MIN after PCD failure), the incidences of surgical complications and MDRO in the SJ-2 group were significantly lower ( $P<0.05$ ).

**Conclusion:** Compared with the step-up approach, the step-jump approach is safer and more effective and can significantly reduce the incidence of MDRO and surgical complications.

**Keywords:** infected pancreatic necrosis, step-up approach, step-jump approach, propensity score match

## Introduction

Acute pancreatitis (AP) is a common and fatal disease worldwide with an incidence of approximately 34/100,000.<sup>1</sup> Approximately 20% of patients with AP develop pancreatic or peripancreatic necrosis, and nearly 30% of them ultimately develop infected pancreatic necrosis (IPN).<sup>2,3</sup> As a common complication in the later course of AP, IPN is characterized by a poor prognosis and a high mortality rate of up to 30%, which often leads to severe complications such as intraabdominal hemorrhage, gastrointestinal fistula, and bleeding.<sup>4-6</sup> The step-up approach, which includes percutaneous catheter drainage (PCD), minimally invasive necrosectomy (MIN), and open necrosectomy (OPN), is regarded as the gold standard of treatment for confirmed or suspected IPN and has been accepted and recommended by most of the relevant guidelines.<sup>7,8</sup>

The step-up approach is advocated because of its minimal surgical trauma and ability to cure nearly one-third of IPN patients without surgery.<sup>9</sup> Although the results from the PANTER trial<sup>9,10</sup> confirmed the safety and superiority of the step-

up approach over the OPN approach in terms of reducing mortality and incidence of complications, a “one-size-fits-all” treatment may have undesirable consequences because of the complexity and heterogeneity of IPN. Excessive attention to the step-up approach may lead to missed surgical opportunities or even death. Therefore, Miao et al proposed that the step-jump approach, an innovation over the traditional step-up approach, should be adopted for early intervention.<sup>11</sup> Considering the strong heterogeneity and varying circumstances of the disease, personalized critical care and highly individualized therapeutic strategies should be applied to IPN treatment.<sup>12,13</sup> For patients requiring surgical intervention, upfront OPN or MIN without PCD may also achieve the desired clinical outcomes. In the present study, we aimed to evaluate the effect of the step-jump approach in two dimensions: (1) direct MIN without PCD and (2) direct OPN after PCD failure. In addition, we explored specific scenario where the step-jump approach should be considered as the primary choice.

## Materials and Methods

### Patient Enrollment and Study Design

A retrospective analysis was conducted using the clinical data of IPN patients admitted to our tertiary referral center between November 2018 and June 2023. The inclusion criteria were as follows: (1) patients conforming to the diagnostic criteria for IPN; (2) those with complete clinical data; (3) aged between 18 and 80 years. The exclusion criteria were as follows: (1) acute exacerbation of chronic pancreatitis; (2) complications with severe systemic disease; (3) coexistence of immunosuppressive factors, such as immunosuppressants or acquired immune deficiency syndrome.

### Procedures

In our center, the selection of appropriate surgical methods involves considering doctors’ opinions, evidence-based medicine, and patients’ preferences. For IPN patients, surgical intervention is preferably performed after 4 weeks.<sup>14</sup> Conversely, PCD is administered to patients with infected or symptomatic necrotic collections during the early period.<sup>7</sup> The step-up approach is primarily applicable to patients with the following characteristics: (1) for walled-off necrosis (WON) with poor liquefaction, PCD allows for egress of necrosis and alleviation of infection symptoms; (2) for WON with great liquefaction and maturity, PCD alone has the potential to cure IPN patients; (3) the puncture route is feasible and safe under ultrasound guidance. In contrast, patients with the following characteristics receive the step-jump therapy: (1) presence of a large amount of dry necrotic tissue, insufficient liquefaction, and no significant relief after conservative treatment or PCD; (2) delays in treatment due to multiple referrals after failing to receive standardized step-up treatment in base hospitals; (3) patients’ preference for surgery to achieve definite and one-time removal of lesions.


All procedures were performed by three experienced pancreatic surgeons who had completed at least 50 laparoscopic or open pancreatic necrosectomy surgeries. The step-up approach is the most common modality for the treatment of IPN following PCD→MIN→OPN. The preferred path for PCD (step-1) is either the median or retroperitoneal approach under the guidance of ultrasound.<sup>15</sup> Clinical improvement was defined as resolution of SIRS/sepsis, or resolution of one or more organ failures in patients without SIRS/sepsis and >25% decrease in the size of the necrotic collection on CT 72 h after intervention. Deterioration of these parameters by other infectious causes was excluded.<sup>16</sup> Clinical failure was defined as the absence of clinical improvement or clinical deterioration.<sup>16</sup> Therefore, if clinical failure occurred 72 h after PCD, a CT scan would be made to assess the drain’s position and any additional possible collections. If the drain was correctly positioned and no additional collections were found, the patient proceeded to the next step.<sup>17</sup> MIN (step-2), such as laparoscopic pancreatic necrosectomy (LPN), minimal access lesser omentum sac pancreatic necrosectomy (MALOSPN), minimal access retroperitoneal pancreatic necrosectomy (MARPN) or videoscopic assisted retroperitoneal debridement (VARD), would then be considered. PCD is preferred if residual infection occurs within the abdominal cavity, even after MIN. Finally, if there was clinical failure even after MIN or any life-threatening complications suddenly occurred, OPN (step-3) would be used as the last rescue measure in the step-up approach.

The step-jump approach represents an upgrade from the traditional step-up approach and is implemented in two situations: (1) patients undergo MIN directly, bypassing PCD; (2) patients initially undergo PCD followed by direct transition to OPN as the final strategy because of the poor efficacy of PCD. In addition, the type of intervention approach and choice of incision depend on the exact distribution of pancreatic necrosis on CT scans or the former path of the PCD.

After surgical debridement of the necrotic tissue, dual-modality drains were left in the cavity to allow egress of necrosis and fluid, as well as for irrigation or flushing. All patients underwent contrast-enhanced CT within 48 h after admission to determine the location and extent of necrosis and to calculate the modified computed tomography severity index (MCTSI). Lactic acid concentration was evaluated using arterial blood gas analysis within 24 h of admission to our hospital. The detailed treatment strategies are presented in Figure 1.

## Classification of Infected Pancreatic Necrosis

Based on years of practice, the clinical experience of our medical center, and the classification system introduced by Baroud et al,<sup>18,19</sup> we developed a new system that classifies IPNs into four types according to necrotic tissue collection sites on CT. (1) Type I (central type): necrotic tissue is limited to the lesser omental sac and its surrounding spaces. (2) Type II (peripheral type): necrotic tissue is limited to the bilateral renal colon and pelvic areas. Three subtypes are derived from this type according to the infection site: IIa, IIb, and IIc. In type IIa and IIb patients, necrotic tissue is localized to the left and right kidney-colon spaces, respectively. In type IIc patients, necrotic tissue is limited to the pelvic–rectal region. (3) Type III (mixed type): necrotic tissue often spreads through various pathways and gaps in the abdominal cavity, leading to widespread infection and necrosis, which can be regarded as the coexistence of type I and type II lesions; the central and peripheral infection foci may be interconnected. (4) Type IV (isolated type): the necrotic tissue is limited to the middle part of the anterior pararenal space, retroperitoneal cavity, and upper segment of the



**Figure 1** Treatment flowcharts for patients in the step-up (SU) and step-jump (SJ) groups. This study comprises two main parts. According to the treatment strategies used in our hospital, 188 patients were enrolled in this study, including 144 patients in the SU and 44 in the SJ groups. Part 1: We aimed to evaluate the effects of omitting PCD by comparing the SU and SJ-1 groups (patients in the SJ-1 group received MIN directly). Part 2: We assessed the effects of direct OPN after PCD failure. Therefore, we selected 43 patients from the SU group who underwent further treatment after PCD failure (SU-2 group). Ten patients in the SJ group received OPN directly after PCD failure and were assigned to the SJ-2 group.

mesenteric root, and the infection site is deep in isolation.<sup>20,21</sup> Table 1 shows the suggested intervention approaches for each type of IPN based on the classification system mentioned above.

## Data Collection and Propensity Score Matching

Baseline data including demographic data, etiology, body mass index (BMI), severity, MCTSI score, Ranson score, laboratory test results, and IPN classification were collected. The data used to evaluate the clinical outcomes included in-hospital mortality, total hospital stay, cost, number of debridements, incidence of organ failure, surgical complications, positive bacterial culture results, and residual infection.

Propensity score matching (PSM) was performed to evaluate the differences in baseline variables between the SU group and SJ-1 group. After comparing the baseline data of the two groups, we found that BMI, MCTSI, percentage of neutrophils, hemoglobin level, IPN classification, and referral rate were significantly different between the two groups. Therefore, we conducted PSM to mitigate the selection bias and ensure that the data were comparable. We considered the Ranson score, MCTSI, and neutrophil percentage as predictors, setting the matching tolerance to 0.05, performing 1:1 matching, and yielding 34 pairs.

## Observation Outcomes

The primary outcome of this study was in-hospital mortality rate. The secondary outcomes of this study were the occurrence of organ failure, number of patients with postoperative complications, presence of residual infection, positive bacterial culture results, number of debridements, and total length and cost of hospital stay. The relevant observables used in this study are listed in Table 2.

## Statistical Analysis

The distribution of variables was examined using the Kolmogorov–Smirnov test. Continuous normally distributed variables are presented as the means  $\pm$  standard deviations and were evaluated using a *t* test. Continuously skewed variables are expressed as medians with interquartile ranges, and the Mann–Whitney *U*-test was used for the difference tests. Categorical variables were compared using the chi-squared test or Fisher’s exact test. A two-sided *P* value  $< 0.05$  indicated a statistically significant difference. These analyses were performed using SPSS software (version 22.0; SPSS, Chicago, IL, USA).

**Table 1** Locations and Suggested Intervention for Every Type of IPN

| IPN type | Detailed Locations in CT Scanning   | Surgical Intervention Pathways                  |
|----------|---|---|
| Type I   | Lesser omental sac and its peripheral space   | PCD/LPN   |
| Type II  |   | PCD, MIAPN, VARD, LPN                           |
| Type IIa | Left kidney-colon space   |   |
| Type IIb | Right kidney-colon space  |   |
| Type IIc | Pelvic-rectal space   |   |
| Type III | Mixed type of type I and type II  | Diversified types of intervention including OPN |
| Type IV  | <ol style="list-style-type: none"> <li>1. Central part of anterior pararenal space, and medium vessels-included retroperitoneal spaces (abdominal aorta and its branches, inferior vena cava)</li> <li>2. Upper mesentery root</li> <li>3. Adjacent to duodenum</li> <li>4. Neck and head of pancreas</li> <li>5. Retropancreatic and introduodenal segments of common bile duct</li> </ol> | Diversified types of intervention including OPN |

**Abbreviations:** IPN, Infected pancreatic necrosis; LPN, Laparoscopic pancreatic necrosectomy; MIAPN, Minimal incision access pancreatic necrosectomy; OPN, Open pancreatic necrosectomy; PCD, Percutaneous catheter drainage; VARD, Video-assisted retroperitoneal debridement.


**Table 2** Definitions for Observational Indicators

|                                   |  |
|-----------------------------------|--|
| Infected pancreatic necrosis      | Fulfillment of either of the following two criteria: (1) extraluminal gas in the pancreatic and/or peri-pancreatic tissues on contrast-enhanced computed tomography (CECT); (2) positive bacterial or fungal culture results with fine needle aspiration (FNA) or other invasive procedures. |
| Respiratory failure               | PaO <sub>2</sub> /FiO <sub>2</sub> <300 or need for mechanical ventilation   |
| Renal failure                     | Creatinine level is more than 177 umol/L after rehydration.  |
| Circulatory failure               | Systolic blood pressure is less than 90 mm Hg despite adequate fluid resuscitation   |
| Organ failure                     | Marshall score of ≥ 2.   |
| Multiple organ failure            | Existence of at least 2 organ failure  |
| New-onset organ failure           | First onset of organ failure requiring intervention at any time in a 24-hour period  |
| Post-operative residual infection | Presentation of residual infected necrotic tissues in the abdominal or retroperitoneal spaces after active surgical treatment, and it usually occurs 2 or 3 months after SAP.  |

## Results

### Characteristics and Treatment of IPN Patients

In total, 188 IPN patients were assessed for eligibility (Figure 2). The patients had a mean age of 44.6±13.1 years, with 117 and 71 being male and female, respectively. In terms of etiology, there were 74 cases of biliary pancreatitis, 65 cases of hyperlipidemic pancreatitis, 20 cases of alcoholic pancreatitis, and 29 cases of pancreatitis of other etiologies including traumatic pancreatitis, autoimmune pancreatitis, and other unknown etiologies. Of the 188 IPN patients, 144 and 44 were in the SU and SJ groups, respectively. Patients cured with PCD alone were assigned to the SU-1 group (n=101), while patients who received a step-up strategy after PCD failure were assigned to the SU-2 group (n=43).

**Figure 2** Flowchart for patient selection.

**Abbreviations:** IPN, infected pancreatic necrosis; SU, Step-up approach; SJ, Step-jump approach.

Patients treated with MIN without PCD were allocated to the SJ-1 group (n=34), while those who underwent OPN after PCD failure were allocated to the SJ-2 group (n=10).

There were no significant differences in age, sex, etiology, preoperative comorbidities, severity, Ranson score, length of ICU stay before intervention, white blood cell count, neutrophil count, albumin level, lactic acid concentration, or procalcitonin level at admission between the SJ-1 and SU groups ( $P>0.05$ ). Before PSM, patients in the SJ-1 group had poor nutritional status and more extensive pancreatic necrosis. They exhibited lower BMI ( $23.3\pm 4.5$  vs  $25.5\pm 4.5$ ,  $P=0.010$ ), lower hemoglobin level ( $105.0[90.0,127.5]$  vs  $120.0[104.0,153.0]$ ,  $P=0.006$ ), lower percentage of neutrophil ( $79.5[72.0,82.2]$  vs  $85.4[80.2,89.4]$ ,  $P<0.001$ ), higher MCTSI scores ( $8[8, 10]$  vs  $8[6, 8]$ ,  $P<0.001$ ), elevated referral rates ( $76.5\% [26/34]$  vs  $51.4\% [74/144]$ ,  $P=0.008$ ), and proportion of type III IPN ( $85.3\% [29/34]$  vs  $54.8\% [79/144]$ ,  $P<0.001$ ) (Table 3).

**Table 3** Patient Baseline Data Comparison Before PSM

| Characteristics                      | SU Group<br>(n=144) | SJ-1 Group<br>(n=34) | P value |
|--------------------------------------|---------------------|----------------------|---------|
| Age (years)                          | 45.0±13.3           | 43.9±13.2            | 0.628   |
| Sex [n (%)]                          |                     |                      | 0.543   |
| Male                                 | 85 (59.0)           | 22 (64.7)            |         |
| Female                               | 59 (41.0)           | 12 (35.3)            |         |
| BMI (Kg/m <sup>2</sup> )             | 25.5±4.5            | 23.3±4.5             | 0.010*  |
| Etiology [n (%)]                     |                     |                      | 0.662   |
| Gallstones                           | 55 (38.2)           | 15 (44.1)            |         |
| Hyperlipidemia                       | 53 (36.8)           | 10 (29.4)            |         |
| Alcoholic                            | 14 (9.7)            | 4 (11.8)             |         |
| Others                               | 22 (15.3)           | 5 (14.7)             |         |
| Degree of severity [n (%)]           |                     |                      | 0.145   |
| MSAP                                 | 62 (43.1)           | 10 (29.4)            |         |
| SAP                                  | 82 (56.9)           | 24 (70.6)            |         |
| ICU stay before intervention [n (%)] |                     |                      | 0.226   |
| Yes                                  | 54 (37.5)           | 9 (26.5)             |         |
| No                                   | 90 (62.5)           | 25 (73.5)            |         |
| Comorbidities [n (%)]                |                     |                      | 0.774   |
| Hypertension                         | 29 (20.1)           | 6 (17.6)             |         |
| Coronary diseases                    | 6 (4.2)             | 2 (5.9)              |         |
| Diabetes                             | 26 (18.1)           | 5 (14.7)             |         |
| Others                               | 17 (11.8)           | 5 (14.7)             |         |
| MCTSI score                          | 8 (6,8)             | 8 (8,10)             | 0.000*  |
| Ranson score                         | 2 (1,3)             | 2.5 (2,3.25)         | 0.297   |

(Continued)

Table 3 (Continued).

| Characteristics                      | SU Group<br>(n=144) | SJ-1 Group<br>(n=34) | P value |
|--------------------------------------|---------------------|----------------------|---------|
| Tertiary Referral [n (%)]            |                     |                      | 0.008   |
| Yes                                  | 74 (51.4)           | 26 (76.5)            |         |
| No                                   | 70 (48.6)           | 8 (23.5)             |         |
| IPN classification [n (%)]           |                     |                      | 0.000*  |
| I                                    | 24 (16.7)           | 2 (5.9)              |         |
| II                                   | 33 (22.9)           | 1 (2.9)              |         |
| III                                  | 79 (54.8)           | 29 (85.3)            |         |
| IV                                   | 8 (5.6)             | 2 (5.9)              |         |
| WBC counts ( $\times 10^9/L$ )       | 13.4 $\pm$ 6.5      | 12.8 $\pm$ 8.3       | 0.657   |
| Percentage of neutrophils (%)        | 85.4 (80.2,89.4)    | 79.5 (72.0,82.2)     | 0.000*  |
| Hb (g/L)                             | 120.0 (104.0,153.0) | 105.0 (90.0,127.5)   | 0.006*  |
| ALB(g/L)                             | 32.4 $\pm$ 5.9      | 32.2 $\pm$ 5.6       | 0.834   |
| Neutrophil count ( $\times 10^9/L$ ) | 10.4 (7.2, 14.8)    | 8.1 (5.1, 12.2)      | 0.130   |
| PCT (ng/mL)                          | 0.7 (0.2,3.9)       | 0.4 (0.2,1.9)        | 0.333   |
| Lactic acid (mmol/L)                 | 1.5 (1.1,2.4)       | 1.0 (0.7, 2.4)       | 0.105   |

Note: \* $P < 0.05$ .

Abbreviations: BMI, Body mass index; IPN, Infected pancreatic necrosis; MSAP, Moderate severe acute pancreatitis; SAP, Severe acute pancreatitis; MCTSI, Modified computer tomography severity index; WBC, White blood cell count; Hb, Hemoglobin; Alb, Albumin; CRP, C-reactive protein; PCT, Procalcitonin.

Regarding clinical outcomes, patients in the SJ-1 subgroup had higher hospital costs (129,573.0 [72,145.5, 184,057.2] vs 71,824.4 [42,937.8, 123,029.5],  $P=0.001$ ) and longer hospital stays (31.0 [18.0, 41.5] vs 20.5 [14.0, 36.0],  $P=0.032$ ). There were no differences in the number of debridements, number of positive bacterial cultures, number of multiple drug-resistant organisms (MDRO), residual infection, organ failure, surgical complications, or mortality ( $P > 0.05$ ). (Table 4)

In the SU group, 101 patients were treated successfully with PCD (SU-1 group), while 43 (29.9%) patients underwent MIN or OPN due to PCD failure (SU-2 group), including 26 patients with LPN; two, MALOSPN; six, MARPN; one, VARD; and eight, OPN. In the SJ group, 26 patients underwent LPN; six, MALOSPN+MARPN; and two, VARD directly without undergoing PCD. Ten patients (22.7%) underwent OPN as the final rescue treatment after PCD failure.

## Clinical Outcomes for IPN Patients After PSM

After PSM, 34 pairs of patients were included in the study, and the baseline variables of the two patient groups were comparable (Table 5). The mortality rates between the two groups were not statistically different (0% [0/34] vs 8.8% [3/34],  $P=0.239$ ). Regarding secondary outcomes, there were no significant differences in the total hospital stay, incidence of organ failure, number of debridements, and residual infection ( $P > 0.05$ ). Patients in the SJ-1 group had higher costs before PSM; however, these differences were no longer evident after PSM (129,573.0 [72,145.5,184,057.2] vs 90,565.5 [49,336.8, 178,133.7],  $P=0.280$ ). The MDRO rate was lower in the SJ-1 group (35.3% [12/34] vs 61.8% [21/34],  $P=0.029$ ). Furthermore, the incidence of surgical complications in the SJ-1 group was lower, especially for new-onset organ failure, gastrointestinal fistula, gastrointestinal bleeding, and venous thrombosis (0% [0/34] vs 5.9% [2/34]; 0% [0/34] vs 11.8% [4/34]; 2.9% [1/34] vs 5.9% [2/34]; 0% [0/34] vs 2.9% [1/34],  $P < 0.001$ ) (Table 6).

**Table 4** Patient Clinical Outcomes Before PSM

| Characteristics                    | SU group<br>(n=144)           | SJ-1 group<br>(n=34)           | P value |
|------------------------------------|-------------------------------|--------------------------------|---------|
| Mortality                          | 12 (8.3)                      | 0 (0)                          | 0.081   |
| Total hospital stay (days)         | 20.5 (14.0,36.0)              | 31.0 (18.0,41.5)               | 0.032*  |
| Total hospital cost (yuan)         | 71,824.4 (42,937.8,123,029.5) | 129,573.0 (72,145.5,184,057.2) | 0.001*  |
| Organ failure [n (%)]              |                               |                                | 0.529   |
| Respiratory failure                | 4 (2.8)                       | 0 (0)                          |         |
| Renal failure                      | 5 (3.5)                       | 0 (0)                          |         |
| Circulatory failure                | 9 (6.3)                       | 3 (8.8)                        |         |
| MOF                                | 2 (1.4)                       | 0 (0)                          |         |
| Positive bacterial culture [n (%)] |                               |                                | 0.071   |
| Blood drainage                     | 30 (20.8)                     | 7 (20.6)                       |         |
| Catheter-drainage infection        | 92 (63.9)                     | 24 (70.6)                      |         |
| MDRO [n (%)]                       |                               |                                | 0.386   |
| Yes                                | 40 (27.8)                     | 12 (35.3)                      |         |
| No                                 | 104 (72.2)                    | 22 (64.7)                      |         |
| Numbers of debridement [n (%)]     |                               |                                | 0.298   |
| Once                               | 32 (22.2)                     | 28 (82.4)                      |         |
| Twice or more                      | 11 (7.6)                      | 6 (17.6)                       |         |
| Residual infection [n (%)]         |                               |                                | 0.077   |
| Yes                                | 41 (28.5)                     | 15 (44.1)                      |         |
| No                                 | 103 (71.5)                    | 19 (55.9)                      |         |
| Surgical complication [n (%)]      |                               |                                | 0.160   |
| Intraabdominal hemorrhage          | 7 (4.9)                       | 3 (8.8)                        |         |
| New-onset organ failure            | 11 (7.6)                      | 0 (0)                          |         |
| Gastrointestinal bleeding          | 3 (2.1)                       | 1 (2.9)                        |         |
| Gastrointestinal fistula           | 6 (4.2)                       | 0 (0)                          |         |
| Venous thrombosis                  | 2 (1.4)                       | 0 (0)                          |         |

**Note:** \* $P < 0.05$ .

**Abbreviations:** ICU, Intensive care unit; MDRO, Multiple drug resistant organism; MOF, Multiple organ failure; PSM, propensity score match.

## Effect of the Step-Jump Approach in Patients with PCD Failure

Owing to the widespread acceptance of the step-up strategy and the lack of consensus or guidelines for direct minimally invasive interventions, PCD is often used as the first step in IPN intervention in clinical practice. However, PCD may fail to control the progression of infection symptoms, leading to the gradual deterioration of clinical symptoms in specific patients. Therefore, it is crucial to adopt timely and effective strategies to prevent PCD failure. To assess the effects of the step-jump approach in patients with PCD failure, we categorized the SU-2 group and SJ-2 groups for new data collection

**Table 5** Patient Baseline Data Comparison After PSM

| Characteristics                      | SU group<br>(n=34) | SJ-I group<br>(n=34) | P value |
|--------------------------------------|--------------------|----------------------|---------|
| Age (years)                          | 44.7±13.0          | 43.9±13.2            | 0.803   |
| Sex [n (%)]                          |                    |                      | 0.618   |
| Male                                 | 20 (58.8)          | 22 (64.7)            |         |
| Female                               | 14 (41.2)          | 12 (35.3)            |         |
| BMI (Kg/m <sup>2</sup> )             | 24.7±3.3           | 23.3±4.5             | 0.135   |
| Etiology [n (%)]                     |                    |                      | 0.503   |
| Gallstones                           | 15 (44.1)          | 15 (44.1)            |         |
| Hyperlipidemia                       | 14 (41.2)          | 10 (29.4)            |         |
| Alcoholic                            | 1 (2.9)            | 4 (11.8)             |         |
| Others                               | 4 (11.8)           | 5 (14.7)             |         |
| Degree of severity [n (%)]           |                    |                      | 0.582   |
| MSAP                                 | 8 (23.5)           | 10 (29.4)            |         |
| SAP                                  | 26 (76.5)          | 24 (70.6)            |         |
| ICU stay before intervention [n (%)] |                    |                      | 0.078   |
| Yes                                  | 16 (47.1)          | 9 (26.5)             |         |
| No                                   | 18 (53.0)          | 25 (73.5)            |         |
| Comorbidities [n (%)]                |                    |                      | 0.147   |
| Hypertension                         | 9 (26.5)           | 6 (17.6)             |         |
| Coronary diseases                    | 3 (8.8)            | 2 (5.9)              |         |
| Diabetes                             | 10 (29.4)          | 5 (14.7)             |         |
| Others                               | 3 (8.8)            | 5 (14.7)             |         |
| MCTSI score                          | 8 (8,10)           | 8 (8,10)             | 0.694   |
| Ranson score                         | 1 (1,3)            | 2.5(2,3.25)          | 0.072   |
| Tertiary Referral [n (%)]            |                    |                      | 0.189   |
| Yes                                  | 21 (59.1)          | 26 (76.5)            |         |
| No                                   | 13 (40.9)          | 8 (23.5)             |         |
| IPN classification [n (%)]           |                    |                      | 0.082   |
| I                                    | 2 (5.9)            | 2 (5.9)              |         |
| II                                   | 4 (11.8)           | 1 (2.9)              |         |
| III                                  | 27 (79.4)          | 29 (85.3)            |         |
| IV                                   | 1 (2.9)            | 2 (5.9)              |         |
| WBC counts (×10 <sup>9</sup> /L)     | 13.4±5.5           | 12.8±8.3             | 0.740   |
| Percentage of neutrophils (%)        | 86.8 (80.4,89.6)   | 79.5(72.0,82.2)      | 0.115   |

(Continued)

**Table 5** (Continued).

| Characteristics                        | SU group<br>(n=34)  | SJ-I group<br>(n=34) | P value |
|--|---------------------|----------------------|---------|
| Hb (g/L)                               | 115.5 (102.5,153.0) | 105.0(90.0,127.5)    | 0.134   |
| ALB(g/L)                               | 31.2±6.3            | 32.2±5.6             | 0.485   |
| Neutrophil count (×10 <sup>9</sup> /L) | 9.8 (7.6, 16.0)     | 8.1 (5.1, 12.2)      | 0.181   |
| PCT (ng/mL)                            | 0.7 (0.3,6.1)       | 0.4 (0.2,1.9)        | 0.120   |
| Lactic acid (mmol/L)                   | 1.5 (1.1,2.2)       | 1.0 (0.7,2.4)        | 0.216   |

**Abbreviations:** BMI, Body mass index; IPN, Infected pancreatic necrosis; MSAP, Moderate severe acute pancreatitis; SAP, Severe acute pancreatitis; MCTSI, Modified computer tomography severity index; WBC, White blood cell count; Hb, Hemoglobin; Alb, Albumin; CRP, C-reactive protein; PCT, Procalcitonin.

**Table 6** Patient Clinical Outcomes After PSM

| Characteristics                    | SU group<br>(n=34)            | SJ-I group<br>(n=34)           | P value |
|------------------------------------|-------------------------------|--------------------------------|---------|
| Mortality                          | 3 (8.8)                       | 0 (0)                          | 0.239   |
| Total hospital stay (days)         | 21.5 (15.8,45.8)              | 31.0 (18.0,41.5)               | 0.361   |
| Total hospital cost (yuan)         | 90,565.5 (49,336.8,178,133.7) | 129,573.0 (72,145.5,184,057.2) | 0.280   |
| Organ failure [n (%)]              |                               |                                | 0.474   |
| Respiratory failure                | 1 (2.9)                       | 0 (0)                          |         |
| Renal failure                      | 0 (0)                         | 0 (0)                          |         |
| Circulatory failure                | 5 (14.7)                      | 3(8.8)                         |         |
| MOF                                | 1 (2.9)                       | 0 (0)                          |         |
| Positive bacterial culture [n (%)] |                               |                                | 0.170   |
| Blood drainage                     | 10 (29.4)                     | 7 (20.6)                       |         |
| Catheter-drainage infection        | 21 (61.8)                     | 24 (70.6)                      |         |
| MDRO [n (%)]                       |                               |                                | 0.029*  |
| Yes                                | 21 (61.8)                     | 12 (35.3)                      |         |
| No                                 | 13(38.2)                      | 22 (64.7)                      |         |
| Numbers of debridement [n (%)]     |                               |                                | 0.283   |
| Once                               | 31 (91.2)                     | 28 (82.4)                      |         |
| Twice or more                      | 3 (8.8)                       | 6 (17.6)                       |         |
| Residual infection [n (%)]         |                               |                                | 0.209   |
| Yes                                | 10 (29.4)                     | 15 (44.1)                      |         |
| No                                 | 24 (70.6)                     | 19 (55.9)                      |         |

(Continued)

**Table 6** (Continued).

| Characteristics               | SU group<br>(n=34) | SJ-1 group<br>(n=34) | P value |
|-------------------------------|--------------------|----------------------|---------|
| Surgical complication [n (%)] |                    |                      | 0.000*  |
| Intraabdominal hemorrhage     | 2 (5.9)            | 3 (8.8)              |         |
| New-onset organ failure       | 2 (5.9)            | 0 (0)                |         |
| Gastrointestinal bleeding     | 2 (5.9)            | 1 (2.9)              |         |
| Gastrointestinal fistula      | 4 (11.8)           | 0 (0)                |         |
| Venous thrombosis             | 1 (2.9)            | 0 (0)                |         |

Note: \* $P < 0.05$ .

Abbreviations: ICU, Intensive care unit; MDRO, Multiple drug resistant organism; MOF, Multiple organ failure; PSM, Propensity score match.

methods. A total of 53 patients were included in this study: 43 in the SU-2 group and 10 in the SJ-2 group. No significant differences were observed between the baseline data of the two groups (Table 7). The clinical mortality rates were similar between the two groups (20.0% [2/10] vs 14.0% [6/43],  $P=0.636$ ). In terms of secondary clinical outcomes, the overall incidence of surgical complications was lower in the SJ-2 subgroup ( $P=0.012$ ), especially new-onset organ failure (0% [0/10] vs 7.0% [3/43]), gastrointestinal fistula (10.0% [1/10] vs 11.6% [5/43]), and venous thrombosis (0% [0/13] vs 2.3% [1/43]) (Table 8). In addition, the MDRO infection rate was lower in the SJ-2 subgroup (20.0% [2/10] vs 41.9% [18/43],  $P < 0.001$ ).

**Table 7** Baseline Data Comparison of SU-2 and SJ-2 Group

| Characteristics            | SU-2 group<br>(n=43) | SJ-2 group<br>(n=10) | P value |
|----------------------------|----------------------|----------------------|---------|
| Age (years)                | 42.9±12.4            | 39.6±9.5             | 0.425   |
| Sex [n (%)]                |                      |                      | 0.096   |
| Male                       | 30 (69.8)            | 10 (100.0)           |         |
| Female                     | 13 (30.2)            | 0 (0)                |         |
| BMI (Kg/m <sup>2</sup> )   | 25.6±5.1             | 25.3±3.6             | 0.850   |
| Etiology [n (%)]           |                      |                      | 0.115   |
| Gallstones                 | 15 (34.9)            | 4(40.0)              |         |
| Hyperlipidemia             | 15(34.9)             | 2(20.0)              |         |
| Alcoholic                  | 6(13.9)              | 2(20.0)              |         |
| Others                     | 7 (16.3)             | 2(20.0)              |         |
| Degree of severity [n (%)] |                      |                      | 0.778   |
| MSAP                       | 7 (16.3)             | 2 (20.0)             |         |
| SAP                        | 36 (83.7)            | 8 (80.0)             |         |

(Continued)

Table 7 (Continued).

| Characteristics                      | SU-2 group<br>(n=43) | SJ-2 group<br>(n=10) | P value |
|--------------------------------------|----------------------|----------------------|---------|
| ICU stay before intervention [n (%)] |                      |                      | 0.722   |
| Yes                                  | 18 (41.9)            | 3 (30.0)             |         |
| No                                   | 25 (58.1)            | 7 (70.0)             |         |
| Comorbidities [n (%)]                |                      |                      | 0.845   |
| Hypertension                         | 1 (2.3)              | 1 (10.0)             |         |
| Coronary diseases                    | 1 (2.3)              | 1 (10.0)             |         |
| Diabetes                             | 1 (2.3)              | 1 (10.0)             |         |
| Others                               | 3 (7.0)              | 2 (20.0)             |         |
| MCTSI score                          | 8(8,10)              | 9(7.5,10)            | 0.623   |
| Ranson score                         | 2 (1,3)              | 2.5(2,4)             | 0.635   |
| Tertiary Referral [n (%)]            |                      |                      | 0.494   |
| Yes                                  | 24 (55.8)            | 7 (70.0)             |         |
| No                                   | 19 (44.2)            | 3 (30.0)             |         |
| IPN classification [n (%)]           |                      |                      | 0.080   |
| I                                    | 6(14.0)              | 2(20.0)              |         |
| II                                   | 2(4.7)               | 0(0)                 |         |
| III                                  | 28(65.1)             | 6(60.0)              |         |
| IV                                   | 7(16.3)              | 2(20.0)              |         |
| WBC counts ( $\times 10^9/L$ )       | 11.6(8.6,18.5)       | 13.4(8.3,19.5)       | 0.829   |
| Percentage of neutrophils (%)        | 82.0 $\pm$ 7.3       | 84.3 $\pm$ 8.8       | 0.397   |
| Hb (g/L)                             | 108.0(92.0,136.0)    | 98.0(83.0,132.5)     | 0.532   |
| ALB(g/L)                             | 31.7 $\pm$ 6.1       | 33.9 $\pm$ 6.1       | 0.323   |
| Neutrophil count ( $\times 10^9/L$ ) | 9.8 (6.8, 16.7)      | 11.7 (6.8, 16.3)     | 0.874   |
| PCT (ng/mL)                          | 0.4(0.2,1.4)         | 0.7(0.4,3.6)         | 0.814   |
| Lactic acid(mmol/L)                  | 2.0 $\pm$ 0.8        | 1.6 $\pm$ 0.5        | 0.526   |

**Abbreviations:** BMI, Body mass index; IPN, Infected pancreatic necrosis; MSAP, Moderate severe acute pancreatitis; SAP, Severe acute pancreatitis; MCTSI, Modified computer tomography severity index; WBC, White blood cell count; Hb, Hemoglobin; Alb, Albumin; CRP, C-reactive protein; PCT, Procalcitonin.

## Discussion

The treatment paradigm for IPN has dramatically evolved from the traditional open necrosectomy to the step-up approach, which consists of a sequence of minimally invasive procedures. However, owing to the poor nutritional status of some patients, rapid increases in abdominal pressure, and delayed treatment in grassroots hospitals, their condition can rapidly deteriorate. Immediate and effective intervention is necessary to promptly clear the lesion, drain pus, and alleviate systemic sepsis and cachexia.<sup>13,22</sup> Therefore, Miao proposed the step-jump approach for specific cases of IPN.<sup>11</sup> Our study revealed that the step-jump approach is safer and more effective than the step-up approach. For IPN patients who

**Table 8** Clinical Outcomes Comparison for SU-2 and SJ-2 Group

| Characteristics                    | SU-2 group<br>(n=43)              | SJ-2 group<br>(n=10)           | P value |
|------------------------------------|-----------------------------------|--------------------------------|---------|
| Mortality                          | 6 (14.0)                          | 2 (20.0)                       | 0.636   |
| Total hospital stay (days)         | 49.0(31.0,67.0)                   | 41.0 (23.5,69.0)               | 0.562   |
| Total hospital cost (yuan)         | 126,882.0<br>(88,411.0,285,300.0) | 147,319.1 (96,207.8,379,721.5) | 0.413   |
| Organ failure [n (%)]              |                                   |                                | 0.799   |
| Respiratory failure                | 4 (9.3)                           | 1 (10.0)                       |         |
| Renal failure                      | 4 (9.3)                           | 1 (10.0)                       |         |
| Circulatory failure                | 8 (18.6)                          | 2 (20.0)                       |         |
| MOF                                | 2 (4.7)                           | 1 (10.0)                       |         |
| Positive bacterial culture [n (%)] |                                   |                                | 0.583   |
| Blood drainage                     | 11 (25.6)                         | 3 (30.0)                       |         |
| Catheter-drainage infection        | 37 (86.0)                         | 8 (80.0)                       |         |
| MDRO [n (%)]                       |                                   |                                | 0.000*  |
| Yes                                | 18 (41.9)                         | 2 (20.0)                       |         |
| No                                 | 25 (58.1)                         | 8 (80.0)                       |         |
| Numbers of debridement [n (%)]     |                                   |                                | 0.442   |
| Once                               | 11(25.6)                          | 4 (40.0)                       |         |
| Twice or more                      | 32 (74.4)                         | 6 (60.0)                       |         |
| Residual infection [n (%)]         |                                   |                                | 0.455   |
| Yes                                | 29 (67.4)                         | 5 (50.0)                       |         |
| No                                 | 14 (32.6)                         | 5 (50.0)                       |         |
| Surgical complication [n (%)]      |                                   |                                | 0.012*  |
| Intraabdominal hemorrhage          | 6 (14.0)                          | 2 (20.0)                       |         |
| New-onset organ failure            | 3 (7.0)                           | 0(0)                           |         |
| Gastrointestinal bleeding          | 0 (0)                             | 0 (0)                          |         |
| Gastrointestinal fistula           | 5(11.6)                           | 1 (10.0)                       |         |
| Venous thrombosis                  | 1 (2.3)                           | 0 (0)                          |         |

**Note:** \* $P < 0.05$ .

**Abbreviations:** ICU, Intensive care unit; MDRO, Multiple drug resistant organism; MOF, Multiple organ failure; PSM, Propensity score match.

directly underwent MIN without PCD and those who directly underwent OPN after PCD failure, the step-jump approach showed a great advantage in reducing the incidence of MDRO and surgical complications.

The step-jump approach has certain advantages over the step-up approach in terms of reducing the MDRO rate. MDROs are often induced by prolonged hospitalization, excessive antibiotic use, and iterative interventions.<sup>23</sup> The aim of the step-jump approach is to minimize the number of interventions required to reduce the length of hospital stay and hospitalization costs, which can simultaneously reduce the MDRO rate. Wu et al reported that severe AP and multidrug-resistant

*Pseudomonas aeruginosa* infections were both independent risk factors for mortality.<sup>24</sup> Another study showed that MDR-*Klebsiella pneumoniae* infection was a strong predictor of mortality in AP patients complicated with septic shock.<sup>25</sup> According to our statistics, MDR-*Klebsiella pneumoniae* was the most common pathogen in our center. In addition, several original studies have shown that high levels of CRP, PCT, and neutrophils are predictors of poor prognosis and susceptibility to infection.<sup>26–29</sup> However, none of the above indices were significantly elevated in the SJ group. This could be explained by the fact that these patients crossed the peak of inflammation at the early stage, but the scope of inflammation and necrosis continued to expand, which could partly explain the greater MCTSI in the SJ group.

As mentioned by Cao et al<sup>30,31</sup> and Han et al<sup>32</sup> the “one-step” approach can dramatically shorten the median length of hospital stay compared with step-up laparoscopic-assisted necrosectomy. Additionally, Bang et al reported that upfront endoscopic necrosectomy offers greater advantages over the step-up approach, significantly improving overall patient status and reducing the number of interventions required.<sup>33</sup> However, our results showed that total hospital stay and cost were similar between the two groups. This could be attributed to the fact that many patients in the SJ group were transferred to our center after prolonged infection and multiple interventions at primary hospitals, making them more susceptible to any surgical intervention. In addition, these patients spent more time waiting for PCD to take effect, which partly explains the lack of disparity.

For patients who have experienced PCD failure, direct OPN administration may also lead to the desired outcomes. A retrospective analysis conducted in Finland showed that these indications were associated with mortality. The mortality risk could be greater for patients who do not show clinical improvement despite aggressive treatment.<sup>34</sup> This suggests that patients requiring open surgery were critically ill, with minimal response to MIN. In this context, the decision to perform open surgery should be viewed as an indicator of poor prognosis, rather than the surgery itself being a factor. It is inappropriate to include critically ill patients in the SJ group and compare them directly with the SU group. Therefore, we divided the SJ group into SJ-1 and SJ-2 groups. Cao et al proposed a “one-step” strategy which involves upfront omission of PCD with immediate MIN.<sup>30</sup> Hence, we utilized PSM to compare the outcomes of omitting PCD by comparing the SU group with the SJ-1 group. Subsequently, we conducted a statistical analysis of patients who experienced PCD failure to investigate improved intervention strategies after PCD failure. The new data collection included patient data from the SU-2 and SJ-2 groups to ensure better comparability between the two groups. Patients who do not respond to PCD or MIN may benefit from OPN.

Another pressing issue that requires immediately attention is determining the indications for the step-jump approach. Given the significant heterogeneity of IPN and varying treatment strategies employed at local medical centers, conducting a prospective clinical trial is nearly unfeasible. Several studies have attempted to identify the factors contributing to the failure of the step-up approach. Hollesmans et al reported that multiple organ failure, male sex, an increasing percentage of pancreatic necrosis, and heterogeneity of necrotic tissue collection are negative predictors of successful catheter drainage in IPN patients.<sup>35</sup> Recently, Li et al reported that early spontaneous bleeding, fungal infection, an APACHE II score of 16 points or more, and other factors were found to be independent risk factors for failure of the minimally invasive step-up approach.<sup>36</sup> Similarly, Huang et al developed a risk score model integrating organ failure, percentage of pancreatic necrosis, extrapancreatic necrosis volume, and mean CT density of extrapancreatic necrosis volume to predict patients with greater opportunity for necrosectomy.<sup>37</sup>

Combining the experience of our medical center with those of previous studies,<sup>35,38</sup> we speculate that the step-up approach may be ineffective in several scenarios: (1) There is extensive dry necrotic tissue with inadequate liquefaction, and conservative treatment or PCD does not provide significant relief. (2) The lesion is located deep within the body, lacking suitable intervention pathways, or is adjacent to critical blood vessels and organs, such as in type IV IPNs. (3) Delays in treatment owing to failure to receive standardized step-up approach treatment in primary hospitals, resulting in progression of the condition through multiple referrals. Therefore, a multidisciplinary team comprising gastroenterologists, intensive care physicians, surgeons, radiologists, and endoscopists is essential. This team can develop individualized and integrated therapies for each patient based on comprehensive assessments, including laboratory tests and imaging studies.

The main limitations of this study are as follows: (1) this was a single-center retrospective analysis, where selection bias could only be reduced, not eliminated, even after PSM; (2) owing to the high outpatient referral rate, medical records from their first admission to local hospitals was often unavailable; (3) endoscopic transluminal necrosectomy was not routinely carried out at our center; and (4) the number of patients in both groups after PSM was relatively small (n=34).

## Conclusions

The step-jump approach is safer and more effective than the step-up approach. Upfront MIN is recommended for patients with a high probability of PCD failure. For patients with PCD failure, direct OPN instead of MIN may lead to the desired outcomes.

## Abbreviations

AP, Acute pancreatitis; BMI, Body mass index; CT, Computed tomography; IPN, Infected pancreatic necrosis; LPN, Laparoscopic pancreatic necrosectomy; MALOSPN, Minimal access lesser omentum sac pancreatic necrosectomy; MARPN, Minimal access retroperitoneal pancreatic necrosectomy; MCTSI, Modified computed tomography severity index; MDRO, Multiple drug-resistant organism; MIN, Minimally invasive necrosectomy; OPN, Open pancreatic necrosectomy; PCD, Percutaneous catheter drainage; PSM, Propensity score match; SJ, Step-jump; SU, Step-up; VARD, Videoscopic assisted retroperitoneal debridement.

## Ethics Approval and Consent to Participate

This study was reviewed and approved by the Ethical Review Committee of the First Affiliated Hospital of Harbin Medical University (No. 2021GS21). This research conforms to the Declaration of Helsinki. Written informed consent was waived due to the retrospective nature of this study. To ensure the confidentiality of patient data, all personal identifiers have been anonymized from the dataset.

## Acknowledgments

We show our full respect and gratitude to all the participants in the study.

## Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

## Funding

The research was supported by: 1.National Natural Science Foundation of China (grant number: 82070658, 82270665); 2.The Science Fund for Excellent Young Scholars of First Affiliated Hospital of Harbin Medical University (grant number: HYD2024YQ01). 3.Natural Science Foundation of Heilongjiang Province of China (grant number: TD2021H001) 4.The Heilongjiang Postdoctoral Fund (grant number: LBH-Z23218).

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Lee PJ, Papachristou GI. New insights into acute pancreatitis. *Nat Rev Gastroenterol Hepatol*. 2019;16(8):479–496. doi:10.1038/s41575-019-0158-2
2. de-Madaria E, Buxbaum JL. Advances in the management of acute pancreatitis. *Nat Rev Gastroenterol Hepatol*. 2023;20(11):691–692. doi:10.1038/s41575-023-00808-w

3. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut*. 2013;62(1):102–111. doi:10.1136/gutjnl-2012-302779
4. Mederos MA, Reber HA, Girgis MD. Acute pancreatitis: a review. *JAMA*. 2021; 325(4):382–390. doi:10.1001/jama.2020.20317
5. Mahapatra SJ, Garg PK. Navigating the stormy sea of infected necrotizing pancreatitis: are we there yet? well almost! *Gastroenterology*. 2022;163(3):578–581. doi:10.1053/j.gastro.2022.06.082
6. Li G, Liu L, Lu T, et al. Gut microbiota aggravates neutrophil extracellular traps-induced pancreatic injury in hypertriglyceridemic pancreatitis. *Nat Commun*. 2023;14(1): 6179. doi:10.1038/s41467-023-41950-y
7. Baron TH, DiMaio CJ, Wang AY, et al. American gastroenterological association clinical practice update: management of pancreatic necrosis. *Gastroenterology*. 2020;158(1):67–75e1. doi:10.1053/j.gastro.2019.07.064
8. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology*. 2013;13(4 Suppl 2):e1–15. doi:10.1016/j.pan.2013.07.063.
9. Van Santvoort HC, Besselink MG, Bakker OJ, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. *N Engl J Med*.;362(16):1491–1502. doi:10.1056/NEJMoa0908821.
10. Hollemans RA, Bakker OJ, Boermeester MA, et al. Superiority of step-up approach vs open necrosectomy in long-term follow-up of patients with necrotizing pancreatitis. *Gastroenterology*. 2019;156(4):1016–1026. doi:10.1053/j.gastro.2018.10.045
11. Huang D, Li Q, Lu Z, et al. From "step-up" to "step-jump": a leap-forward intervention for infected necrotizing pancreatitis. *Chin Med J*.;135(3):285–287. doi:10.1097/CM9.0000000000001877.
12. Hamada T, Tsujimae M, Nakai Y, et al. Beyond one-size-fits-all: size-oriented criteria for the step-up treatment of walled-off pancreatic necrosis. *Clin Gastroenterol Hepatol*. 2024;22(2):433–435. doi:10.1016/j.cgh.2023.05.026
13. Ning C, Ouyang H, Shen D, et al. Prediction of survival in patients with infected pancreatic necrosis: a prospective cohort study. *Int J Surg*.;110(2):777–787. doi:10.1097/JS9.0000000000000844.
14. Trikudanathan G, Wolbrink DRJ, van santvoort hc, et al. Current concepts in severe acute and necrotizing pancreatitis: an evidence-based approach. *Gastroenterology*. 2019;156(7):1994–2007e3. doi:10.1053/j.gastro.2019.01.269
15. Huang J, Li L, Chen Y, et al. Early short-term abdominal paracentesis drainage in moderately severe and severe acute pancreatitis with pelvic ascites. *BMC Surgery*. 2023;23(1): 363. doi:10.1186/s12893-023-02269-z
16. Bang JY, Arnoletti JP, Holt BA, et al. An endoscopic transluminal approach, compared with minimally invasive surgery, reduces complications and costs for patients with necrotizing pancreatitis. *Gastroenterology*. 2019;156(4):102. doi:10.1053/j.gastro.2018.11.031
17. Shenvi S, Gupta R, Kang M, et al. Timing of surgical intervention in patients of infected necrotizing pancreatitis not responding to percutaneous catheter drainage. *Pancreatology*. 2016;16(5):778–787. doi:10.1016/j.pan.2016.08.006
18. Baroud S, Chandrasekhara V, Storm AC, et al. Novel classification system for walled-off necrosis: a step toward standardized nomenclature and risk-stratification framework. *Gastrointest Endosc*. 2023;97(2):300–308. doi:10.1016/j.gie.2022.09.019
19. Telaprolu H, Srinu D, Mangipudi UK, et al. Novel classification system for walled-off pancreatic necrosis: a step in the right direction. *Gastrointest Endosc*. 2023;98(5):873. doi:10.1016/j.gie.2023.05.060
20. Sui YH, Sun B. Preliminary exploration of the typing of infected pancreatic necrosis and rethinking of the surgical interventions. *Zhong Hua Wai Ke Za Zhi*. 2021;59:601–607. doi:10.3760/cma.j.cn112139-20210127-00054
21. Luo Y, Li L, Kong R, et al. Acute necrotizing pancreatitis: challenges and interventions—a narrative review. *J Pancreatol*. 2022. doi:10.1097/JP9.0000000000000103
22. Gunjan D, Mahapatra SJ, Garg PK. Upfront necrosectomy for infected necrotising pancreatitis: a promising strategy? *Lancet Gastroenterol Hepatol*. 2024;9(1):2–3. doi:10.1016/S2468-1253(23)00369-2
23. Cheng G, Wang D, Zhu P, et al. Clinical characteristics of acute pancreatitis patients with multidrug-resistant bacterial infection. *Infect Drug Resist*. 15: 1439–1447. doi:10.2147/IDR.S354347
24. Wu D, Lu W, Huang Y, et al. The impact of multi-drug resistant pseudomonas aeruginosa infections on acute pancreatitis patients. *BMC Infect Dis*.;23(1):340. doi:10.1186/s12879-023-08230-y.
25. Wu D, Ding J, Jia Y, et al. Predictors of mortality in acute pancreatitis complicated with multidrug-resistant Klebsiella pneumoniae infection. *BMC Infect Dis*.;21(1):977. doi:10.1186/s12879-021-06709-0.
26. Li W, Ou L, Fu Y, et al. Risk factors for concomitant infectious pancreatic necrosis in patients with severe acute pancreatitis: a systematic review and meta-analysis. *Clin Res Hepatol Gastroenterol*. 2022;46(5):101901. doi:10.1016/j.clinre.2022.101901
27. Tran A, Fernando SM, Rochweg B, et al. Prognostic factors associated with development of infected necrosis in patients with acute necrotizing or severe pancreatitis-A systematic review and meta-analysis. *J Trauma Acute Care Surg*.;92(5):940–948. doi:10.1097/TA.00000000000003502.
28. Li G, Chen H, Liu L, et al. Role of interleukin-17 in acute pancreatitis. *Front Immunol* 2021. 12: 674803. doi:10.3389/fimmu.2021.674803
29. Mann B, Bhandohal J, Kalha I, et al. Relevance of procalcitonin levels as a marker of severity and predictor of mortality, initiation and duration of antibiotics in patients admitted with acute pancreatitis: a retrospective cohort study. *Clin Exp Gastroenterol* 2024. 17: 31–39. doi:10.2147/CEG.S453345
30. Cao F, Duan N, Gao C, et al. One-Step versus step-up laparoscopic-assisted necrosectomy for infected pancreatic necrosis. *Dig Surg*. 2020;37(3):211–219. doi:10.1159/000501076
31. Zheng Z, Lu J, Cao F, et al. "One-step" approach versus "Step-up" approach minimally invasive treatment for infected pancreatic necrosis: a study protocol for a single-center, prospective, randomized controlled trial. *BMC Gastroenterol*.;22(1):41. doi:10.1186/s12876-022-02116-0.
32. Han SB, Chen D, Chen QY, et al. One-step laparoscopic pancreatic necrosectomy versus surgical step-up approach for infected pancreatic necrosis: a case-control study. *World J Emerg Med*. 2022;13(4):274–282. doi:10.5847/wjem.j.1920-8642.2022.058
33. Bang JY, Lakhtakia S, Thakkar S, et al. Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial. *Lancet Gastroenterol Hepatol*. 2024;9(1):22–33. doi:10.1016/S2468-1253(23)00331-X
34. Husu HL, Kuronen JA, Leppäniemi AK, et al. Open necrosectomy in acute pancreatitis-obsolete or still useful? *World J Emerg Surg*.;15(1):21. doi:10.1186/s13017-020-00300-9.
35. Hollemans RA, Bollen TL, van Brunschot S, et al. Predicting success of catheter drainage in infected necrotizing pancreatitis. *Ann Surg Apr*. 2016;263(4):787–792. doi:10.1097/SLA.0000000000001203

36. Li G, Li S, Cao L, et al. Nomogram development and validation for predicting minimally invasive step-up approach failure in infected necrotizing pancreatitis patients: a retrospective cohort study. *Int J Surg.*;109(6):1677–1687. 10.1097/JS9.0000000000000415.
37. Huang D, Lu Z, Li Q, et al. A risk score for predicting the necessity of surgical necrosectomy in the treatment of infected necrotizing pancreatitis. *J Gastrointest Surg.* 2023;27(10):2145–2154. doi:10.1007/s11605-023-05772-z
38. Babu RY, Gupta R, Kang M, et al. Predictors of surgery in patients with severe acute pancreatitis managed by the step-up approach. *Ann Surg.* 2013;257(4):737–750. doi:10.1097/SLA.0b013e318269d25d

Journal of Inflammation Research

Dovepress

## Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-inflammation-research-journal>